Arcus Biosciences (NYSE:RCUS) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Arcus Biosciences (NYSE:RCUS) from a sell rating to a hold rating in a research report report published on Sunday.

Other equities research analysts have also recently issued reports about the company. Truist Financial set a $30.00 price objective on Arcus Biosciences in a research note on Friday, December 12th. HC Wainwright boosted their target price on shares of Arcus Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Wells Fargo & Company raised their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Monday, October 20th. Bank of America lifted their price objective on shares of Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a research report on Friday, November 28th. Finally, Citigroup reissued a “buy” rating on shares of Arcus Biosciences in a research report on Friday, December 12th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.00.

Arcus Biosciences Price Performance

Shares of RCUS opened at $21.83 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. The company has a 50 day moving average price of $22.87 and a 200-day moving average price of $16.13. Arcus Biosciences has a fifty-two week low of $6.50 and a fifty-two week high of $26.40. The stock has a market capitalization of $2.36 billion, a PE ratio of -6.35 and a beta of 0.77.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.33) by $0.06. The company had revenue of $26.00 million for the quarter, compared to analyst estimates of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. Arcus Biosciences’s revenue was down 45.8% compared to the same quarter last year. During the same period last year, the company posted ($1.00) earnings per share. Equities analysts predict that Arcus Biosciences will post -3.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Arcus Biosciences

In related news, President Juan C. Jaen sold 82,997 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $24.71, for a total value of $2,050,855.87. Following the completion of the transaction, the president owned 954,063 shares in the company, valued at $23,574,896.73. This trade represents a 8.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Terry J. Rosen sold 28,947 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total value of $633,360.36. Following the sale, the chief executive officer owned 2,220,553 shares in the company, valued at approximately $48,585,699.64. The trade was a 1.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 422,060 shares of company stock worth $9,286,202. 9.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arcus Biosciences

Large investors have recently bought and sold shares of the company. GAMMA Investing LLC raised its position in Arcus Biosciences by 17.5% during the 4th quarter. GAMMA Investing LLC now owns 3,230 shares of the company’s stock worth $77,000 after buying an additional 482 shares during the last quarter. Amalgamated Bank raised its holdings in shares of Arcus Biosciences by 3.9% during the third quarter. Amalgamated Bank now owns 19,533 shares of the company’s stock worth $266,000 after purchasing an additional 736 shares during the last quarter. Creative Planning lifted its position in Arcus Biosciences by 2.7% during the third quarter. Creative Planning now owns 29,629 shares of the company’s stock valued at $403,000 after purchasing an additional 771 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in Arcus Biosciences by 8.0% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,398 shares of the company’s stock valued at $142,000 after purchasing an additional 1,294 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in Arcus Biosciences by 9.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 18,873 shares of the company’s stock worth $440,000 after purchasing an additional 1,649 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.